It has been described that IFN-γ-deficient mice are significantly protected against liver injury and hepatic fibrosis in a model of non-alcoholic steatohepatitis (41), and it has further been demonstrated that anti-IFN-γ treatment results in lower ALT levels and hepatocellular injury following 48 hours of reperfusion in a model of 60-minute partial warm ischemia (42). This evidence concerns the gene IFNG and metabolic dysfunction-associated steatohepatitis.